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Summary 
L Excretion of urinary kallikrein was flormal in 
13 out of 15 patients with uncomplicated essential 
hypertension, 
2i Frusemide increased urinary kallikrein ex­
cretion in nörhiotensive subjects and in patients 
with essential hypertension. The stimulating effect 
of frusemide on urinary kallikrein was significantly 
diminished in patients with essential hypertension. 
3. No correlations of urinary kallikrein with 
sodium, potassiurff, and aldosterone excretion were 
found. 
4. The results do not support the idea that 
urinary kallikrein plays a primary role in the patho-
genesis of essential hypertension. 
Key words: essential hypertension, frusemide, 
kalfikrem. 
Abbreviation: PR A, plasma renin activity. 
f fitrodü<itiört 
There is evidence that urinary kallikrein is formed 
in and secreted by the kidney (Nustad* 1970). The 
role of the ihtrarenai kallikrein—kinirl system in 
renal handling of water and electrolytes and its 
interaction with otter renal endocrine systems has 
been Studiod extensively within the last few years 
(Obika, 1978). Subnormal urinary kallikrein excre-
tion in essential hypertension was first reported by 
Elliot & Nüzüm (1934) and confirmed by Mar-
golftiS* Geller; Pisano & Sjoerdsma (1971)» and this 
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suggested a possible role in the pathogenesis of 
high blood pressure. 
The aim of this study was to examine urinary 
kallikrein excretion in respect of its relationship to 
water and electrolyte excretion, and to the renin-
angiotensin-aldosterone system in normotensive 
Subjects and in patierits with essential hyperten-
sion. . 
Subjects and methods 
Fourteen male normotensive subjects (mean age 31 
± 2-4 years) and 15 male patients with mild (WHO 
I ; η = 10) or moderate essential hypertension 
(WHO I I ; /z = 5) (meari age 36 ± 2»7 years) were 
included in the study. Average blood pressure in 
the normal subjects was 117 ± 2-4/77 ± 1-6 
mmHg and in the hypertensive patients was 163 ± 
6-4/1Ö5 ± 2-8 mmHg. Antihypertensive treatment 
had been withdrawn for at least 2 weeks* Diuretic 
agents had been withdrdwh for ät least 4 weeks 
before the study. 
Studies werfc performed Under ambulatory con-
ditions without dietary restrictions. Urine was col-
lected for 24 h in 8 h periods (period 1 ! 07.00-
iS.OO hours; period 2: 15.0O-2100 hours; period 
3: 23.00-07.00 Hours). On the following morning, 
after ä 30 miri resting period, blobd samples were 
taken for estimation of plasma renin activity 
(PRA) and plasma creatinine, thereafter 40 nig of 
frusemide (Lasix) was given intravenously and 
urine" was collected for arimher 30 min period. A t 
the end of the collection period, blood was again 
taken for estimation of PRA. 
In each urine sample creatinine* sodium, potas-
sium, and aldosterone were estimated. 
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Urinary kallikrein was estimated by four dif­
ferent methods. 
(1) Amidolytic activity of urinary kallikrein was 
measured with a chromogenic tripeptide substrate 
(S 2266; ΚΑΒΪ, Stockholm) in non-dialysed as well 
as in dialysed urines. 
(2) Esterolytic activity of urinary kallikrein was 
estimated with acetyl-L-phenylalanyl-L-arginine-
ethylester (APAE) as substrate in dialysed urines 
only (Fiedler, Geiger, Hirschauer & Leysath, 
1978). 
Values for urinary kallikrein activity from assays 
(1) and (2) are expressed in units of substrate-
splitting activity (units/1 = //mol m i n - 1 1 - 1 ) -
(3) Bioassay utilized the vasodepressor effect of 
urinary kallikrein, tested in anaesthetized dogs 
(Nembutal, 40 mg/kg) after intravenous injections 
of dialysed urine. 
(4) Urinary kallikrein was also estimated by a 
direct radioimmunoassay in non-dialysed as well as 
in dialysed urine samples (Mann, Geiger, Goring, 
Lipp, Fink, Keipert & Karl , 1979). 
Bioassay and radioimmunoassay values were 
standardized by using a purified human urinary 
kallikrein preparation (Geiger, Stuckstedte, Förg-
Brey & Fink, 1979), and are expressed as ng/ml. 
Urine samples were dialysed against distilled 
water for 24 h at + 4 ° C . The non-dialysed urine 
samples (assay 1 and 4) for comparison were 
stored for 24 h at + 4 ° C without any pretreatment. 
Sodium, potassium and creatinine were 
measured by standard methods. Aldosterone ex-
cretion was measured by radioimmunoassay, PRA 
was estimated as previously described (Distler, 
Keim, Cordes, Philipp & Wolff, 1978). 
The data were analysed by the Student's /-test. 
Linear dependencies were examined by regression 
analysis. Data are given as mean values ± SEM. 
Results 
The amidolytic activity of urinary kallikrein is 
shown in Table 1. There were no significant differ-
ences in activities between the periods 1, 2 and 3, 
both in normal subjects and in patients with hyper-
. tension. Individual values varied considerably. In 
normal subjects the range was between 347 and 
1658 units/24 h; in the hypertensive patients the 
range was between 175 and 2089 units/24 h (non-
dialysed urine). Urinary kallikrein in no more than 
two patients was found to be diminished in com-
parison with the values for normal subjects. 
Dialysis of urine led to a consistent increment of 
the amidolytic activity in both groups by about 
25%. 
Urinary kallikrein increased after frusemide in 
both groups (normal, Ρ < 0-001; hypertensive, Ρ < 
0-05); mean activity after frusemide, however, was 
significantly less (P < 0-05) in hypertensive 
patients. 
PRA did not differ in recumbency, whereas 
frusemide-stimulated PRA was lower in hyper­
tensive patients (P < 0-05). No difference could be 
demonstrated in urinary volume and the excretion 
of sodium, potassium and aldosterone, or in the 
creatinine clearance in both groups, neither under 
basal conditions nor after frusemide ad­
ministration. 
No correlation was found between urinary 
kallikrein and the excretion of sodium, potassium 
and aldosterone, the creatinine clearance and 
resting and stimulated PRA. Kallikrein excretion 
per 24 h, however, correlated significantly with 
urinary volume in the normal subjects only (non-
dialysed urine: r = 0-65, Ρ < 0-05). 
The following correlations were obtained with 
the four methods for estimation of urinary kalli­
krein: (1) AP AE (j>) vs S 2266 (x) in dialysed urine 
(n = 113): y = 56-40.V + 1-80; r = 0-97; (2) 
bioassay (v) vs S 2266 (x) in dialysed urine (n = 
71): y = 0-44* + 0-76; r = 0-80; (3) radio­
immunoassay (y) vs S 2266 (x) in non-dialysed 
urine (n = 22): y = M 8 x - 2-25; r = 0-95; (4) 
radioimmunoassay (y) in non-dialysed vs radio­
immunoassay (x) in dialysed urine (/z = 22); y — 
0-96.X + 3-17; r = 0-95. 
Discussion 
We did not find a significant difference in urinary 
kallikrein excretion between patients with un­
complicated essential hypertension and age-
matched normotensive control subjects. A normal 
excretion was also reported by Lawton & Fitz 
(1977), who compared young male patients with 
mild essential hypertension with age-matched 
control subjects. Other authors reported a normal 
kallikrein excretion in labile essential hyper­
tension, but a decreased kallikrein excretion in 
the established condition (Nekrasova, Lantsberg, 
Chernova & Khukharev, 1970; Overlack, Stumpe, 
Zywzok, Ressel & Krück, 1978). These findings 
suggest that subnormal kallikrein excretion is 
secondary to the hypertensive process. 
Frusemide stimulates kallikrein excretion in man 
(Seino, Abe, Irokawa, Ito, Yasujima, Sakurai, 
Chiba, Saito, Ritz, Kusaka, Miyazaki & 
Yoshinaga, 1978), as was observed also in this 
study. However, in hypertensive patients the effect 
T A B L E 1. Urinary kallikrein, volume, sodium, potassium and aldosterone, creatinine clearance, and plasma renin activity in normotensive subjects (NS) 
and patients with essential hypertension (EH) under basal conditions (NS, η = 14; EH, n= 15 ) and after intravenous frusemide ( 4 0 mg) (NS, η = 11; 
EH, η = 1 5 ) 
P R A , Plasma renin activity; C c r creatinine clearance; control, periods 1 + 2 + 3 (see text). Mean values ± S E M are shown. *P<005; * * / > < 0 · 0 1 * 
* * • / > < 0 - 0 0 1 . 
Period Kallikrein (S 2266) PRA Volume Sodium Potassium C C r Aldosterone 
(m units/period) . ( n g l r ' m l " 1 ) (ml/period) (mmol/period) (mmol/period) (ml min" 1 1-73 m^2) (//g/pcriod) 
Non-dialysed Dialysed 
urine urine 
07.00-15.00 hours NS" 281 ± 39 377 ± 40* 437 ± 58 60 ± 9 35-0 ±3 -2 115 ± 10 5-9 ± 1-1 
EH 317 ± 55 401 ±60*** 466 ± 4 2 66 ± 6 31-5 ± 2 - 0 120 ± 9 6 2 ± 0 7 
15.00-23.00 hours NS 270 ± 3 1 335 ± 37 534 ± 75 ' 76 ± 7 29-9 ± 3 - 7 106 ± 7 3-6 ± 0 5 
EH 271 ± 4 4 329 ± 50*** 522 ± 6 8 80 ± 9 29.4 + 3-1 119 + 7 5-3 + 0-6 
23.00^07.00 hours NS 252 ± 4 0 359 ± 49* 377 ± 4 1 5 1 + 6 15·I ± 1-9 97 ± 4 3-0 ± 0 - 5 
EH 264 ± 3 8 347 ±.44*** 433 ± 55 65 ± 9 15-3 ± 1-2 102 ± 5 3-6 ± 0 - 5 
07.00-07.00 hours NS 808 ± 102 1066 ±117* 1348 ± 151 184 ± 17 800 ± 7-3 106 ± 5 125 ± 2 0 
EH 850 ± 129 1072 ± 146*** 1421 ± 138 211 ± 2 0 76-2 ± 4 . 5 113 ± 5 ' 15-1 ± 1-5 
Control (30 min) NS 20-7 ± 3-0 2-4 + 0-3 29 ± 4 3-7 ± 0 - 4 f-6 + 0-2 105 ± 5 
EH 22-4 ± 3 0 2-1 ± 0 - 3 30 ± 3 4 4 ± 0 4 1-6 ± 0 1 113 ± 5 
Frusemide (30 min) NS 48-6 ± 7-5 7-0 ± 0 - 8 521 ± 18 66-6 ± 2-5 8-3 ± 0-4 106 ± 5 
EH 32-6 ±4 -6 4-4 ± 0-7 503 + 24 661 ± 2 9 7-9 ± 0 - 4 99 + 6 
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was less pronounced. According to the findings of 
Croxatto, Albertini, Corthorn & Rosas (1977) 
increments of kallikrein excretion in rats are caused 
by an increased synthesis in the kidney. Therefore 
our findings could indicate a reduced synthesis of 
glandular kallikrein after stimulation in hyperten­
sive patients. 
Interassay correlations showed that the synthetic 
substrates used are appropriate for the estimation 
of urinary kallikrein. Dialysis of urine samples, 
leads to art increase of the amidolytic activity. 
However, the amounts of kallikrein measured in 
non-dialysed and dialysed urine samples by radio­
immunoassay did not differ. It seems possible that 
a kallikrein inhibitor as was found in renal tubules 
in rats (Geiger & Mann, 1976) is excreted in urine 
and removed by dialysis. 
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